CSL Hong Kong Aleviate Human Coagulation Factor VIII 500IU/von Willebrand factor 1000IU complex, Powder for injection (50 IU/mL FVIII)

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

Von willebrand factor, Quantity: 1000 IU; Factor VIII, Quantity: 500 IU

Available from:

CSL Behring Australia Pty Ltd

INN (International Name):

Factor VIII,Von willebrand factor

Pharmaceutical form:

Injection, solution

Composition:

Excipient Ingredients: water for injections

Administration route:

Intravenous

Therapeutic indications:

Aleviate is indicated for: ? the treatment of bleeding episodes including surgical bleeding in patients with von Willebrand disease when desmopressin (DDAVP) treatment is ineffective or contraindicated. ? the treatment and prophylaxis of bleeding associated with factor FVIII deficiency due to haemophilia A.

Product summary:

Visual Identification: Clear, colourless solution; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Authorization status:

Listed (Export Only)

Authorization date:

2004-06-17